BioSpace News Archive

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is supporting Professor Sachin Gupte, a pharmacologist at the New York Medical College (Valhalla, NY, USA), in his endeavours to find a drug treatment for the lung damage that can result from Covid-19 infection. S

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced that the companies have entered into a strategic licensing agreement for the product candidate SEL-212. SEL-212 is a combination of Selecta’s tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme

The Biotechnology Innovation Organization released new data on the bioscience industry in the United States this week during the BIO Digital conference.

Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its initial public offering of 14,400,000 shares of common stock at a public offering price of $18.00 per share.

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering price of $19.00 per share. I

A company formed as a spinout from Cancer Research UK-funded science at The Institute of Cancer Research, London, has been publicly launched – revealing $32.5m in funding and a library of innovative anti-cancer compounds

Decoding the immune response to the virus from thousands of patient samples may contribute to the development of novel diagnostics, vaccines and therapeutics Data will be updated regularly and made freely available to researchers and public health officials around the world

Confirm BioSciences, a leading provider of comprehensive screening tools and solutions, today announced that a COVID-19 antibody test the company offers, manufactured by Healgen Scientific, performed exceptionally well in a recent serological test validation project conducted by National Institutes of Health (NIH), National Cancer Institute (NCI) and National Institute of Allergy and Infectious Disease (NIAID)

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the openings of two new plasma collection centers in the St. Louis metropolitan area.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 14,000,000 of its shares of common stock at a purchase price of $1.25 per share in a registered direct offering.